Search results
Results from the WOW.Com Content Network
Shares of bioscience firm Amyris (AMRS) skyrocketed more than 70% on Tuesday after the company announced a collaboration deal focused on developing, licensing, and commercializing cannabinoid ...
Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors can now consider renewable products company Amyris (NASDAQ:AMRS) as a "marijuana stock." The Emeryville, California-based firm signed a deal to license cannabinoid products. This sent ...
The company went public on NASDAQ on September 28, 2010 (AMRS). [5] In November 2011, Amyris acquired Lansing, Michigan-based renewable chemicals and products company, Draths Corporation, for $7 million in stock. [6] ATEL Capital Group acquired a stake in Amyris in December 2011. [7]
Business Insider's Oracles of Wall Street list highlights the top forecasters among economists, strategists, and analysts each year. The most accurate forecasts of 2024: Seeking nominations for ...
Amyris, Inc. (AMRS) closed at $3.96 in the latest trading session, marking a +1.02% move from the prior day.
Belski's target reflects about 14% upside from Friday's close; the strategist already has a 6,100 year-end target for 2024. This puts Belski's forecast for returns in 2025 at 9.8%, right in line ...
With markets now cheering soft inflation prints and signs the economy is still growing, Lee thinks a similar narrative plays out in 2024. "2023 was a year where the [stock market] technicians got ...